Recent Advances in Retroperitoneal Sarcoma: Diagnosis, Surgery, Radiotherapy, Systemic Therapy, and Recurrence Management
DOI:
https://doi.org/10.31557/RRO.2026.12.1.223Abstract
Introduction: Retroperitoneal sarcomas (RPS) are rare malignant mesenchymal tumors that present at large size, near critical organs and major vessels, and comprise diverse histological subtypes, making diagnosis and management challenging. This review summarizes evidence on RPS diagnosis, pathology, treatment, recurrence, and future directions.
Methods: A narrative literature review was conducted using PubMed and contemporary evidence sources, focusing on publications from 2020 onward. Guidelines, consensus statements, randomized trials, systematic reviews, meta-analyses, and observational studies on RPS diagnosis, pathology, treatment, surveillance, and recurrence were reviewed.
Results: Contrast-enhanced computed tomography remains the primary imaging modality, while magnetic resonance imaging is used selectively. Image-guided core needle biopsy is recommended to establish histology and guide treatment. For localized disease, surgery at experienced sarcoma centers remains the main potentially curative treatment, guided by histology and multidisciplinary decision-making. Following the STRASS trial, preoperative radiotherapy is not routinely recommended but may benefit selected patients with well-differentiated or low-grade dedifferentiated liposarcoma. Systemic therapy has a limited role in localized disease but is being investigated in neoadjuvant and advanced or metastatic settings using histology-directed approaches. Long-term surveillance is essential because recurrence is common; recurrent disease requires individualized assessment and may involve repeat surgery, radiotherapy, systemic therapy, or combined approaches.
Conclusions: RPS management has evolved toward a histology-driven, multidisciplinary approach. Surgery remains the cornerstone, while radiotherapy and systemic therapy should be selected according to histology, tumor biology, recurrence risk, disease extent, and patient characteristics. International collaboration, prospective trials, molecular characterization, and biomarker-driven strategies are needed to improve outcomes and personalize treatment.




3.jpg)

